Durham, NC, United States of America

Thangaraju Murugesan

USPTO Granted Patents = 3 


 

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 160(Granted Patents)


Location History:

  • Cary, NC (US) (2018)
  • Durham, NC (US) (2016 - 2020)

Company Filing History:


Years Active: 2016-2020

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Thangaraju Murugesan: Innovator in Medicament Delivery Systems

Introduction

Thangaraju Murugesan is a notable inventor based in Durham, NC (US). He has made significant contributions to the field of medicament delivery systems, particularly focusing on nicotine and its therapeutic applications. With a total of 3 patents, his work is paving the way for advancements in health-related technologies.

Latest Patents

Murugesan's latest patents include innovative devices and methods for the delivery of a medicament. One of his key inventions relates to enhancing nicotine or other medicament concentrations in a gaseous carrier. This method is adaptable for delivering nicotine for therapeutic effects in various diseases, especially for tobacco product use cessation, substitution, and harm reduction. The disclosure also encompasses various devices and design principles for implementing these methods effectively.

Career Highlights

Thangaraju Murugesan is currently employed at Philip Morris Products S.A., where he continues to develop and refine his inventions. His work is instrumental in addressing public health challenges associated with tobacco use and nicotine delivery.

Collaborations

Some of his notable coworkers include Jed E. Rose and Seth David Rose, who contribute to the innovative environment at Philip Morris Products S.A. Their collaborative efforts enhance the research and development of new technologies in the field.

Conclusion

Thangaraju Murugesan's contributions to medicament delivery systems highlight his role as an influential inventor in the health technology sector. His innovative approaches are crucial for advancing therapeutic solutions for nicotine-related health issues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…